The Arg-Gly-Asp sequence resides in the cell attachment region offibronectin. Arg-Gly-Asp-containing peptides support fibroblast attachment, inhibit fibroblast adhesion to fibronectin, and inhibit fibronectin binding to thrombinstimulated platelets. In view of the similarities between the binding of fibronectin, fibrinogen, and von Willebrand factor to stimulated platelets, we have examined the effects of ArgGly-Asp-containing peptides on the interaction of these latter two adhesive proteins with platelets. Gly-Arg-Gly-Asp-Ser-Pro was used as a prototype peptide, and this hexapeptide inhibited fibrinogen binding to ADP and thrombin-stimulated platelets in the 10-200 jaM range. The inhibition exceeded 90% at high concentrations of peptide and was observed in the presence of either calcium or magnesium. Platelet aggregation was also inhibited by the peptide in this dose range. The hexapeptide inhibited fibrinogen binding to platelets with receptors fixed in an exposed state, indicating direct interference with the ligand-platelet interaction. The peptide was 1/2 to 1/3rd as potent in inhibiting fibrinogen as fibronectin binding to platelets, but fibrinogen and von Willebrand factor binding were inhibited to an identical extent. Conservative amino acid substitutions for the arginine, glycine, or aspartic acid markedly reduced inhibitory activity and the Asp-Gly-Arg sequence was inactive. These results indicate that Arg-Gly-Asp-containing peptides can inhibit the binding of the three adhesive proteins to stimulated platelets, establishing a basic common feature between the interaction of these molecules with platelets.
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Platelet attachment, spreading, and aggregation on extracellular matrices are central events in thrombus formation. These events can be regulated by a family ofplatelet adhesive glycoproteins-fibrinogen, fibronectin, and von Willebrand factor (vWF). Fibrinogen is a cofactor for platelet aggregation (1) (2) (3) , fibronectin supports platelet attachment and spreading reactions (4) (5) (6) (7) , and vWF is important in platelet attachment to and spreading on subendothelial matrices (7) (8) (9) . At a mechanistic level, the role of these adhesive proteins in platelet functions can be attributed to their interaction with specific binding sites on the cell surface. Although binding of these proteins to resting platelets is not detected, saturable interactions can be demonstrated with platelets stimulated by agonists such as thrombin (10) (11) (12) (13) (14) (15) . The binding of all three proteins to thrombin-stimulated platelets is divalent ion dependent (11, 14, 16, 17) , and platelets from patients with Glanzmann thrombasthenia exhibit decreased capacity to bind all three proteins (11, 18, 19) . Synthetic peptides corresponding in sequence to the carboxyl-terminal region of the y chain of fibrinogen inhibit the binding of all three molecules to platelets (20) , suggesting that common mechanisms may be involved in these interactions.
Recent studies have demonstrated that the Arg-Gly-Asp sequence within fibronectin is involved in the cell attachment function of this glycoprotein (21, 22) . Arg-Gly-Asp-containing peptides support fibroblast attachment and inhibit attachment of these cells to fibronectin (21) (22) (23) . We have recently shown that Arg-Gly-Asp-containing peptides inhibit the binding of fibronectin to thrombin-stimulated platelets, and the same structure-function relationships necessary for such peptides to support fibroblast attachment were required for inhibition of fibronectin binding to platelets (24) . The Arg-Gly-Asp sequence exists in a number of other proteins (22, 23) . Several of these proteins support cell attachment, and synthetic Arg-Gly-Asp-containing peptides have been shown to inhibit specific functions associated with these proteins (22, 25, 26) . One protein containing the Arg-Gly-Asp sequence is fibrinogen, in which it resides at residues 95-97 and 572-574 of the 611-amino acid Aa chain (27, 28) . The presence of an Arg-Gly-Asp sequence within vWF has also been recently demonstrated (29) . In view of this sequence homology and the common features of the interaction of platelet adhesive proteins with the cell, we have examined the effects ofArg-Gly-Asp-containing peptides on the binding of fibrinogen and vWF to platelets.
MATERIALS AND METHODS
Adhesive Proteins-Platelet Interactions. Human platelets were isolated from fresh blood collected into acid citrate/dextrose by differential centrifugation followed by gel filtration on Sepharose 2B in divalent ion-free Tyrode's buffer (pH 7.4) containing 2% bovine serum albumin as described (10, 14, 16) . The adhesive proteins were isolated from fresh human plasma. Fibrinogen was isolated by differential ethanol precipitation and ammonium sulfate fractionation (30) . In addition, the fibrinogen preparations were then passed over a gelatin-Sepharose column to remove fibronectin. Fibronectin was isolated by gelatin-Sepharose affinity chromatography (31) . vWF was purified from the cryoprecipitates of fresh-frozen plasma by gel filtration on Sepharose 2B (32) . Each of the adhesive proteins was radioiodinated as described (20) . The radiolabeled ligands were bound by their respective monospecific antibodies but not by antibodies to the other two adhesive proteins. Platelet binding of each of these radiolabeled proteins as performed in this study has also been described (20 
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The radiolabeled proteins were then added at final concentrations of 0.3 gM for 125I-labeled fibrinogen and 125I-labeled fibronectin, and 0.4 gg/ml for 125I-labeled vWF. Plateletbound ligand was separated from free ligand by centrifugation through 20% sucrose for 3 min in a Beckman microfuge. As noted (20) (24, 33, 34 24-hr hydrolyzates of the peptides were subjected to amino acid analyses on an automated Beckman amino acid analyzer. Two preparations of the prototype peptide, Gly-Arg-GlyAsp-Ser-Pro were used in this study, and each was >95% homogenous by these criteria.
Platelet Aggregation. Washed human platelets were suspended at a final concentration of 1 x 108 platelets per ml in Tyrode's buffer containing 1 mM calcium, 0.3 ,M fibrinogen, and the selected dose of Gly-Arg-Gly-Asp-Ser-Pro. Aggregation was initiated by addition of 10 ,uM ADP and was measured in a dual-channel aggregometer (Sienco DP-247E, Morrison, CO) at 37°C at a stirring rate of 1000 rpm as described (10) .
RESULTS
Gly-Arg-Gly-Asp-Ser-Pro has been used as a prototype of the Arg-Gly-Asp-containing peptides, and its effects on fibrinogen binding to platelets has been examined (Fig. 1) (24, 33, 34) , indicating that the peptide can directly inhibit fibrinogen binding to its exposed receptor. Since higher concentrations of the peptide were required (ID50 = 80-95 ,uM) for inhibition of '25I-labeled fibrinogen binding to the fixed platelets, an additional effect of the peptide on platelet stimulation and/or induction of the fibrinogen binding sites may also occur.
As shown in Fig. 2 , Gly-Arg-Gly-Asp-Ser-Pro inhibited the steady-state binding of 125I-labeled fibrinogen to ADP-stimulated platelets in the presence of either calcium or magnesium. The peptide appeared to be slightly more inhibitory in the presence of magnesium/EGTA, but suppression was readily observed in the presence of either divalent ion. Agents that inhibit fibrinogen binding to platelets should also interfere with platelet aggregation (12, 35) . This prediction is documented with Gly-Arg-Gly-Asp-Ser-Pro (Fig. 3A) . At a high dose of the peptide (400 ,uM), platelet aggregation induced by 10 AtM ADP was completely inhibited, but the decrease in light transmission indicative of the change in platelet shape from a discoid to a more spherical form was not affected. In Fig. 3B , the effect of various doses of Gly-ProGly-Asp-Ser-Pro on the initial rate of platelet aggregation and on the inhibition of 125I-labeled fibrinogen binding to platelets has been correlated. In the range of 30 to 200 ,M Gly-ArgGly-Asp-Ser-Pro, these events were linearly related.
The effect of Gly-Arg-Gly-Asp-Ser-Pro on vWF binding to platelets was examined. Various doses of the peptide were assessed for their capacity to inhibit fibrinogen, fibronectin, and vWF binding to the same preparation of thrombinstimulated platelets (Fig. 4) . The peptide inhibited vWF binding in a dose-dependent manner, and its capacity to inhibit fibrinogen and vWF binding was virtually identical. The peptide was, however, 3-fold more potent in inhibiting fibronectin binding (ID50 = 9 ,M for fibronectin vs. 27 ,uM for fibrinogen and vWF). A similar relationship was also observed with thrombin-stimulated fixed platelets (not shown). At 100 ,uM Gly-Arg-Gly-Asp-Ser-Pro, vWF binding to platelets in the presence of ristocetin was not inhibited (Fig. 4) .
The structural specificity of the inhibition of fibrinogen binding by Arg-Gly-Asp-containing peptides was analyzed and is summarized in platelets (24) and for fibroblast attachment activity (22, 23) . vWF and fibrinogen binding were inhibited to an identical extent by Gly-Arg-Gly-Asp-Ser-Pro, compatible with a similarity in their binding to stimulated platelets (20, 37, 38) . These observations, coupled with our previously reported data on the inhibition offibronectin binding by these peptides (24) , provide direct evidence for a closely related binding mechanism for these adhesive proteins to platelets. It is noteworthy that the Arg-Gly-Asp peptides were 2-to 3-fold more potent in inhibiting fibronectin, as contrasted to fibrinogen and vWF binding to platelets. This result contrasts with the identical effect of the fibrinogen --chain peptides on platelet binding of the three adhesive proteins (20) and suggests that the mechanism of inhibition by Arg-Gly-Asp may not be precisely identical for each protein.
A (39) . These observations are consistent with the inhibition of adhesive protein binding by these peptides being mediated by the interaction of the Arg-Gly-Asp-containing peptides with the cell. Similar preliminary evidence has been provided for binding of the fibrinogen y-chain peptides to platelets (36) . Thus, Arg-GlyAsp peptides and fibrinogen y-chain peptides may bind to platelets, exhibit a fine structural specificity for inhibitory activity, and are effective in inhibiting adhesive protein binding in the micromolar range. The issue as to whether these peptide sets define the same, related, or distinct recognition specificities is not presently known. It should be noted in this regard that the Ala-Gly-Asp-Val peptide, the only apparent primary structural homology between the two peptide sets, did not inhibit fibrinogen binding to platelets. The interrelationships between the binding sites defined by (29) further emphasizes the need to precisely evaluate the role ofthis peptide sequence in the platelet binding functions of the adhesive proteins. While the definitive role of these peptide sequences in these interactions remains to be elucidated, it can be unequivocally concluded from the present study that Arg-Gly-Asp-containing peptides inhibit fibrinogen, fibronectin, and vWF binding to platelets.
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